PROTAC targeted protein degraders: the past is prologue

M Békés, DR Langley, CM Crews - Nature reviews Drug discovery, 2022‏ - nature.com
Targeted protein degradation (TPD) is an emerging therapeutic modality with the potential to
tackle disease-causing proteins that have historically been highly challenging to target with …

COVID-19: Discovery, diagnostics and drug development

T Asselah, D Durantel, E Pasmant, G Lau… - Journal of …, 2021‏ - Elsevier
Summary Coronavirus disease 2019 (COVID-19) started as an epidemic in Wuhan in 2019,
and has since become a pandemic. Groups from China identified and sequenced the virus …

Employee engagement practices during COVID‐19 lockdown

N Chanana, Sangeeta - Journal of public affairs, 2021‏ - Wiley Online Library
In the present business situation during the COVID‐19 pandemic, employee engagement
has become one of the utmost prominent primacies for human resource managers and …

Mechanism and inhibition of the papain‐like protease, PLpro, of SARS‐CoV‐2

T Klemm, G Ebert, DJ Calleja, CC Allison… - The EMBO …, 2020‏ - embopress.org
The SARS‐CoV‐2 coronavirus encodes an essential papain‐like protease domain as part of
its non‐structural protein (nsp)‐3, namely SARS2 PLpro, that cleaves the viral polyprotein …

COVID-19: drug targets and potential treatments

C Gil, T Ginex, I Maestro, V Nozal… - Journal of medicinal …, 2020‏ - ACS Publications
Currently, humans are immersed in a pandemic caused by the emerging severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), which threatens public health …

Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review

X Li, Y Song - European journal of medicinal chemistry, 2023‏ - Elsevier
Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) identified in 2003
infected∼ 8000 people in 26 countries with 800 deaths, which was soon contained and …

Progress and challenges in targeting the SARS-CoV-2 papain-like protease

H Tan, Y Hu, P Jadhav, B Tan… - Journal of medicinal …, 2022‏ - ACS Publications
SARS-CoV-2 is the causative agent of the COVID-19 pandemic. The approval of vaccines
and small-molecule antivirals is vital in combating the pandemic. The viral polymerase …

A global review on short peptides: frontiers and perspectives

V Apostolopoulos, J Bojarska, TT Chai, S Elnagdy… - Molecules, 2021‏ - mdpi.com
Peptides are fragments of proteins that carry out biological functions. They act as signaling
entities via all domains of life and interfere with protein-protein interactions, which are …

Potent noncovalent inhibitors of the main protease of SARS-CoV-2 from molecular sculpting of the drug perampanel guided by free energy perturbation calculations

CH Zhang, EA Stone, M Deshmukh… - ACS central …, 2021‏ - ACS Publications
Starting from our previous finding of 14 known drugs as inhibitors of the main protease
(Mpro) of SARS-CoV-2, the virus responsible for COVID-19, we have redesigned the weak …

Design of SARS-CoV-2 PLpro inhibitors for COVID-19 antiviral therapy leveraging binding cooperativity

Z Shen, K Ratia, L Cooper, D Kong, H Lee… - Journal of medicinal …, 2021‏ - ACS Publications
Antiviral agents that complement vaccination are urgently needed to end the COVID-19
pandemic. The SARS-CoV-2 papain-like protease (PLpro), one of only two essential …